Capabilities by Region: Continental Europe
Greenhill has considerable advisory experience in Continental Europe. Our Managing Directors and professionals have advised clients on transactions involving many of the leading companies in the region and have access to a vast network of corporate relationships throughout Continental Europe. Greenhill established its presence in Continental Europe in November 2000 with the opening of a Frankfurt office. Greenhill further expanded its presence with the opening of a Madrid office in 2017 and a Paris office in 2020.
For more information on Greenhill’s advisory practice in Continental Europe and our capabilities in the region, please contact President David Wyles in our London office, Managing Director Philip Meyer Horn in our Frankfurt office, Javier Gonzalez in our Madrid Office or Amélie Négrier-Oyarzabal in our Paris office.
Below we highlight a few of the transactions on which we have advised in this region:
Recent Transactions
Sort By
Morris Corporation
Advised Morris Corporation, a leading independent player in Australia’s remote facilities management sector, on its sale to Sodexo SA, a France-based leading global facilities services company
Thermamax
Advised the shareholders of Thermamax, a leading family-owned manufacturer of highly engineered high temperature insulation solutions on the sale of the Company
LCH.Clearnet SA
Advised LCH.Clearnet Group Limited, a leading multi-asset class European clearing house, on a sale of LCH.Clearnet SA, its French-regulated operating subsidiary, to Euronext N.V. that was ultimately terminated
Portfolio of 119 marketed and development pipeline products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 119 marketed and development pipeline products to Rivopharm SA
Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).